Another $VTAE, Vitae Pharmaceuticals Inc (NASDAQ:VTAE)

New Post Public Reply Private Reply Replies (0) Message Board
fitzkarz Pharaoh #9349
Another $VTAE,

Vitae Pharmaceuticals Inc (NASDAQ:VTAE) Receives Consensus Recommendation of “Buy” from Brokerages
March 14th, 2016 - By Faye Duncan - 0 comments

Vitae Pharmaceuticals logoVitae Pharmaceuticals Inc (NASDAQ:VTAE) has been given an average rating of “Buy” by the six brokerages that are covering the stock, Market Beat.com reports. Three research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $21.50.

VTAE has been the topic of a number of recent research reports. Stifel Nicolaus lowered shares of Vitae Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 4th. Wedbush reiterated an “outperform” rating and set a $20.00 price objective on shares of Vitae Pharmaceuticals in a research note on Friday, December 11th. Piper Jaffray reiterated a “buy” rating and set a $18.00 price objective on shares of Vitae Pharmaceuticals in a research note on Tuesday, December 29th. Wells Fargo started coverage on shares of Vitae Pharmaceuticals in a research note on Thursday, December 3rd. They set an “outperform” rating on the stock. Finally, Zacks Investment Research upgraded shares of Vitae Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 5th.

In other news, CEO Jeffrey S. Hatfield sold 22,524 shares of the firm’s stock in a transaction that occurred on Wednesday, December 23rd. The shares were sold at an average price of $17.00, for a total value of $382,908.00. Following the sale, the chief executive officer now directly owns 293,897 shares in the company, valued at approximately $4,996,249. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Donald J. Hayden, Jr. sold 16,130 shares of the firm’s stock in a transaction that occurred on Tuesday, December 29th. The shares were sold at an average price of $18.00, for a total transaction of $290,340.00. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Vitae Pharmaceuticals stock. Candriam Luxembourg S.C.A. purchased a new position in shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 133,000 shares of the company’s stock, valued at approximately $2,407,000. Candriam Luxembourg S.C.A. owned approximately 0.61% of Vitae Pharmaceuticals as of its most recent filing with the SEC.

Vitae Pharmaceuticals (NASDAQ:VTAE) traded up 2.31% during trading on Monday, reaching $4.88. 573,488 shares of the company’s stock were exchanged. The firm’s market cap is $106.73 million. The stock’s 50 day moving average price is $8.57 and its 200 day moving average price is $12.03. Vitae Pharmaceuticals has a 52-week low of $4.15 and a 52-week high of $18.71.

Vitae Pharmaceuticals (NASDAQ:VTAE) last issued its quarterly earnings data on Thursday, March 3rd. The company reported ($0.52) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.10. The company earned $0.09 million during the quarter, compared to the consensus estimate of $0.14 million. Vitae Pharmaceuticals’s revenue for the quarter was down 42.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.40) earnings per share. Equities research analysts anticipate that Vitae Pharmaceuticals will post ($2.23) EPS for the current fiscal year.

Vitae Pharmaceuticals, Inc is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform.
12 Month Chart for NASDAQ:VTAE

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Vitae Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson Controls FY26 Results Highlight Growth Momentum

Updated Category News Views 141

Unpacking Johnson Controls' Fiscal 2026 Performance You know, it's not often that a company hits a home run with back-to-back quarters, but Johnson Controls (NYSE:JCI) seems to be swinging for the fences as they wrap up fiscal 2026. What we've got here is a robust set of financial results, showcasing not just growth but momentum that's got investors humming. We're talking...

Continue Reading
EZRA Loop Fuses Human Insight and AI for Managers

Updated Category News Views 134

Hybrid Coaching: The Future is Here If someone told me five years ago that human coaches and AI would team up to churn out better business leaders, I'd have a laugh. But here we are with EZRA Loop, an inventive mix of flesh-and-blood wisdom and algorithmic precision hitting the streets. This might seem like the latest buzzword pie in the sky to some, but there's a real...

Continue Reading
IBM Targets AI Agent Security with New Releases

Updated Category News Views 185

The AI Agent Surge: A Governance Challenge Platforms are hungry for AI agents, but enterprises are drowning in a sea of responsibilities. They bring in these digital workers, pumping them up like competitors puffing their chests. But there's a hitch: you can’t let these agents run wild in sensitive systems, or it’ll be chaos—like letting a bull loose in a china...

Continue Reading
Ensign Group Faces Securities Fraud Lawsuit Amid Scandal

Updated Category News Views 34

Ensign's Legal Storm: Investors on Edge Man, you can't ignore the weighty allegations pounding on Ensign Group's door right now. The skilled nursing giant, under the ticker NASDAQ:ENSG, is feeling the heat from a securities class action filed against them, and my gut tells me this isn't going to blow over quietly. This case sure looks like a financial tempest that could...

Continue Reading
SoftwareOne Secures Leadership in Gartner Report Again

Updated Category News Views 130

A Glance at SoftwareOne's Unyielding Dominance Call it a streak, call it consistency—either way, SoftwareOne's nailed it yet again, bagging the Leader spot in Gartner's Magic Quadrant for SAM Managed Services for the seventh straight year. Yep, seven years running. This ain't just a piece of paper to hang on the office wall. It's a testament to their grit in helping...

Continue Reading
Midland, Michigan Tops 2027 Retirement Destinations

Updated Category News Views 240

Down-to-Earth Findings for Retirees in 2027 Look, when we're talking about settling down after years of the daily grind, it's crystal clear what folks really care about: not blowing through their savings in a heartbeat. No wonder Midland, Michigan, nailed the No. 1 spot yet again in U.S. News & World Report's 2027 Best Places to Retire. And this ain't just a fluke; they...

Continue Reading
Co-Diagnostics Nearing India TB Test Launch By 2026

Updated Category News Views 7

Co-Diagnostics Gears Up for Indian TB Test Market Picture this: Co-Diagnostics, a molecular diagnostics player, is on the brink of a significant leap toward expanding its footprint in India with its TB test. The stage is set, with a clinical study already turning in results as solid as old boots. We're talking sensitivity hovering around 97.3% and specificity at...

Continue Reading
Perpetua Wins $40M U.S. Army Deal: Eyes Tungsten Boost

Updated Category News Views 94

Perpetua's Strategic Move in Mineral Exploration Forget the sleazy diner talk for a sec. We're diving into a strategic American push to revive homegrown tungsten supply. Perpetua Resources is dancing a new jig with a solid $40 million award from the U.S. Army, assisting in this military-driven goal through the Defense Ordnance Technology Consortium. Talk about a smart...

Continue Reading
Pizza & Hope: Little Caesars Serves WV Communities

Updated Category News Views 125

Rolling Out Dough and Kindness in West Virginia In a world that's more uncertain than a penny stock, here comes a story that'll warm even the coldest heart: Little Caesars is sending their Love Kitchen into West Virginia, aiming to serve piping hot pizza to about 8,000 folks in need. Fueled by the efforts of local franchisee Vicki Dunn-Marshall and her team, they're...

Continue Reading
China Leads Electrification; US Faces Stagnation Risk

Updated Category News Views 155

China Races Ahead in Electrification If you ever doubted China's resolve to lead the green charge, the latest Electrification Competitiveness Index should make you think again. They're pacing ahead, while the rest of the world seems content with playing catch-up. Created by the savvy folks over at We Mean Business Coalition with RMI's backing, this index sizes up the...

Continue Reading

Top 5 Most Recently Viewed Articles

Unveiling the DTEN D7X 27: A Game-Changer for Collaboration

Updated Category News Views 206

DTEN D7X 27 Released as a Premier Collaboration Device DTEN, a leading name in video conferencing and collaboration technology, has recently launched the DTEN D7X 27. This innovative device is designed to optimize collaboration in huddle rooms, kiosks, and various workspaces that have limited space. The device is a significant step forward, elevating the collaboration...

Continue Reading
Baird Raises Price Target for S&P Global on Positive Performance

Updated Category News Views 184

Overview of S&P Global's Recent Performance Baird, a well-known financial advisory firm, has recently enhanced its outlook on S&P Global (NYSE: SPGI) shares, increasing the price target from $536 to an impressive $575. This reflects Baird's confidence in the company's overall performance and maintains a status of Outperform for the stock. Analyst Insights on Company...

Continue Reading
Cryptocurrency Market Trends: An Uncertain Path Forward

Updated Category News Views 116

Cryptocurrency Markets Overview In the recent downturn, cryptocurrency markets have slipped significantly. Notably, Bitcoin is struggling to maintain its value near the $110,000 mark, showcasing how volatile the market can be. Ethereum also sees challenges with a current trading price around $4,545.28. As the crypto landscape evolves, each currency is impacted by various...

Continue Reading
Memo Therapeutics Achieves Milestone in Potravitug Trial

Updated Category News Views 180

Significant Milestone Reached in Clinical Trial for Potravitug Schlieren / Zurich, Switzerland – Memo Therapeutics AG (or “MTx”), an innovative biotech company advancing unique immune solutions, proudly announces that it has successfully enrolled the last patient in its extensive Phase II clinical trial for the BK polyomavirus (BKV)-neutralizing antibody,...

Continue Reading
Gee Automotive Companies Shines as a Top Employer on Latest List

Updated Category News Views 179

Gee Automotive Companies Celebrated as a Leading Employer Gee Automotive Companies has recently earned impressive recognition in the realm of employee satisfaction. Garnering the #2 position among extra-large companies on the well-regarded 2025 'Best Places to Work in Washington' list, this honor reflects the company's unyielding commitment to creating an exceptional work...

Continue Reading